As of Friday close, MEDNAX Inc.’s (NYSE:MD) stock was up $0.69, moving up 3.90 percent to $18.38. The average number of shares traded per day over the past five days has been 1,082,200 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.33 fall in that time frame. In the last twenty days, the average volume was 780,170, while in the previous 50 days, it was 635,384.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, MD stock retreated -21.92%. Shares of the company fell to $17.17 on 05/12/22, the lowest level in the past month. A 52-week high of $35.67 was reached on 01/04/22 after having rallying from a 52-week low of $17.17. Since the beginning of this year, MD’s stock price has dropped by -32.45% or -$8.83, and marked a new high 2 times. However, the stock has declined by -48.48% since its 52-week high.
MEDNAX Inc. (MD) last reported insider trading activity 123 days ago on Jan 11. MEDEL ROGER MD, the Director of the company, disposed of 40,107 shares for $26.58 on Jan 11. It resulted in a $1,066,044 divestment by the insider. MEDEL ROGER MD sold 59,893 shares at an average price of $26.44 on Jan 10. The insider now owns 779,557 shares following the transaction. On Jan 05, Director MEDEL ROGER MD sold 12,639 shares at $27.42 apiece. The transaction was valued at $346,561.
Right now, MEDNAX Inc. (MD) has a P/E ratio of about 19.27. The stock’s beta is 2.05. Besides these, the trailing price-to-sales (P/S) ratio of 0.83, the price-to-book (PB) ratio of 1.79, and the price-to-cash flow ratio of 52.10 may also be considered.
In the three months ended September 29, MEDNAX Inc.’s quick ratio stood at 1.60, while its current ratio was 1.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.92, and the total debt-to-equity ratio was 0.92. In the year ended September 29, operating margins totaled 8.20%. Based on annual data, MD earned $513.24 million in gross profit and brought in $1.91 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 8.50%. Return on equity (ROE) for the past 12 months was 10.80%.
In MEDNAX Inc.’s quarter-end financial report for September 29, it reported total debt of $149.0 million against cash and short-term investments of $89.58 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. MD’s revenue rose 7.36% to $498.53 million during the quarter, while net income inched up to $482.23 million. While analysts expected MEDNAX Inc. to report $0.42 quarterly earnings, the actual figure was $0.46 per share, beating the consensus estimate by 9.50%. During the quarter, the company generated $48.45 million in EBITDA. The liabilities of MEDNAX Inc. were 1.46 billion at the end of its most recent quarter ended September 29, and its total debt was $1.07 billion. The value of shareholders’ equity is $87.26 million.
This quick technical analysis looks at MEDNAX Inc.’s (MD) price momentum. With a historical volatility rate of 29.51%, the RSI 9-day stood at 34.48% on 13 May.
With respect to its five-day moving average, the current MEDNAX Inc. price is down by -1.76% percent or -$0.33. At present, MD shares trade -22.05% below its 20-day simple moving average and -28.92% percent below its 100-day simple moving average. However, the stock is currently trading approximately -21.32% below its SMA50 and -37.86% below its SMA200.
Stochastic coefficient K was 9.77% and Stochastic coefficient D was 5.67%, while ATR was 0.91. Given the Stochastic reading of 19.77% for the 14-day period, the RSI (14) reading has been calculated as 33.78%. As of today, the MACD Oscillator reading stands at -0.51, while the 14-day reading stands at -1.35.
SVB Leerink launched its rating on MEDNAX Inc. (NYSE: MD) to a Mkt perform in a note to investors on September 27, 2021. MEDNAX Inc. (MD) has been rated Hold by analysts. According to 1 brokerage firm , MD is a sell, and 7 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate MEDNAX Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $23.00, the current consensus forecast for the stock is $16.00 – $30.00. Based on these forecasts, analysts predict MEDNAX Inc. (MD) will achieve an average price target of $22.78.